Sign in Subscribe
Diseases

Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights

Strategic Insights

— 2 min read

The psychosis in Parkinson’s and Alzheimer’s Disease market presents a significant challenge for patients and caregivers, with symptoms of hallucinations and delusions significantly impacting patient quality of life. In Parkinson’s disease, psychosis affects 20-70% of patients, often emerging in later stages due to disease progression and dopaminergic treatment effects. Similarly, in Alzheimer’s disease, psychosis also presents as delusions and hallucinations, commonly linked to cognitive decline and neurodegeneration.

Key Takeaways:

  • The diagnosed prevalent cases of Parkinson’s disease (PD) in the seven major markets (7MM) totaled approximately 2.6 million in 2023, with the US and combined EU4 plus UK each accounting for about 45%, and Japan representing 10%.
  • Alzheimer's disease (AD) affected 6.3 million diagnosed individuals in the US in 2023, with females representing 65% of cases.
  • The psychosis market in Parkinson’s and Alzheimer’s disease across the seven major markets (7MM) was valued at approximately USD 1.29 billion in 2023 and is expected to grow steadily through 2034.
  • Emerging therapies, including NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others, are expected to drive significant growth in the market in the coming years.
  • Standardized treatment guidelines are limited, and pimavanserin (34 mg/day) is considered first-line therapy for Parkinson’s disease psychosis, as it is the only FDA-approved drug for this condition and has a low risk of severe adverse effects.
  • There is a pressing need for more effective and targeted therapies for psychosis in both Alzheimer’s and Parkinson’s disease, as current treatments are often limited by side effects such as hallucinations, confusion, and nausea.
  • Several late-stage drug candidates, such as KarXT, Ulotaront, and FANAPT, are under development and show promise in expanding treatment options for psychosis associated with neurodegenerative diseases.

Statistics:

  • USD 1,290 million: The psychosis in Parkinson’s disease and Alzheimer’s disease market in the 7MM was valued at approximately USD 1,290 million in 2023.
  • 45%: The US and combined EU4 plus UK each accounted for about 45% of the total diagnosed prevalent cases of Parkinson’s disease in 2023.
  • 65%: Females represented 65% of Alzheimer's disease (AD) diagnosed individuals in the US in 2023.
  • 2.6 million: The diagnosed prevalent cases of Parkinson’s disease in the seven major markets (7MM) totaled approximately 2.6 million in 2023.
  • 6.3 million: Alzheimer's disease (AD) affected 6.3 million diagnosed individuals in the US in 2023.
  • USD 1.29 billion: The psychosis market in Parkinson’s and Alzheimer’s disease across the seven major markets (7MM) was valued at approximately USD 1.29 billion in 2023.

Sources:

  • "Psychosis in Parkinson’s and Alzheimer’s Disease - Market Insights, Epidemiology, and Market Forecast-2034”
  • DelveInsight
  • Karuna Therapeutics
  • Sunovion Pharmaceuticals
  • Intra-Cellular Therapies
  • Acadia Pharmaceuticals
  • FDA
  • Alzheimer's Disease Facts and Figures 2023
  • Parkinson’s disease Prevalence and Incidence
  • Best practices in psychotherapeutic treatment and rehabilitation of psychosis in Parkinson’s and Alzheimer’s disease

Read more